Relay Therapeutics Net Worth
Relay Therapeutics Net Worth Breakdown | RLAY |
Relay Therapeutics Net Worth Analysis
Relay Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Relay Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Relay Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Relay Therapeutics' net worth analysis. One common approach is to calculate Relay Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Relay Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Relay Therapeutics' net worth. This approach calculates the present value of Relay Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Relay Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Relay Therapeutics' net worth. This involves comparing Relay Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Relay Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Relay Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Relay Therapeutics' net worth research are outlined below:
| Relay Therapeutics generated a negative expected return over the last 90 days | |
| Relay Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 25.55 M. Net Loss for the year was (341.97 M) with profit before overhead, payroll, taxes, and interest of 1.38 M. | |
| Relay Therapeutics currently holds about 1.05 B in cash with (300.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: Down -27.93 percent in 4 Weeks, Heres Why Relay Therapeutics Looks Ripe for a Turnaround |
Relay Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Relay Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Relay Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Relay Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Relay Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Relay Therapeutics backward and forwards among themselves. Relay Therapeutics' institutional investor refers to the entity that pools money to purchase Relay Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Logos Global Management Lp | 2024-06-30 | 2.6 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.5 M | Geode Capital Management, Llc | 2024-06-30 | 2.4 M | Mpm Oncology Impact Management Lp | 2024-09-30 | 2 M | Boxer Capital Llc | 2024-09-30 | 1.8 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 1.7 M | Finepoint Capital Lp | 2024-06-30 | 1.6 M | Alphabet Inc | 2024-06-30 | 1.6 M | Goldman Sachs Group Inc | 2024-06-30 | 1.5 M | Sb Investment Advisers (uk) Ltd | 2024-09-30 | 27.9 M | Vanguard Group Inc | 2024-09-30 | 14.5 M |
Follow Relay Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 776.66 M.Market Cap |
|
Project Relay Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.41) | (0.43) | |
| Return On Capital Employed | (0.46) | (0.48) | |
| Return On Assets | (0.41) | (0.43) | |
| Return On Equity | (0.45) | (0.43) |
When accessing Relay Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Relay Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Relay Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Relay Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Relay Therapeutics. Check Relay Therapeutics' Beneish M Score to see the likelihood of Relay Therapeutics' management manipulating its earnings.
Evaluate Relay Therapeutics' management efficiency
Relay Therapeutics has return on total asset (ROA) of (0.2687) % which means that it has lost $0.2687 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4269) %, meaning that it created substantial loss on money invested by shareholders. Relay Therapeutics' management efficiency ratios could be used to measure how well Relay Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.43 in 2024. Return On Capital Employed is likely to drop to -0.48 in 2024. At this time, Relay Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 792.1 M in 2024, whereas Total Assets are likely to drop slightly above 838.5 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 6.13 | 6.44 | |
| Tangible Book Value Per Share | 6.12 | 6.42 | |
| Enterprise Value Over EBITDA | (3.37) | (3.53) | |
| Price Book Value Ratio | 1.79 | 1.00 | |
| Enterprise Value Multiple | (3.37) | (3.53) | |
| Price Fair Value | 1.79 | 1.00 | |
| Enterprise Value | 1.3 B | 683.8 M |
Evaluating the management effectiveness of Relay Therapeutics allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Relay Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Enterprise Value Revenue 18.1672 | Revenue 10 M | Quarterly Revenue Growth 43.279 | Revenue Per Share 0.076 | Return On Equity (0.43) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Relay Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Relay Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Relay Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Relay Therapeutics Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 6th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 30th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 11th of September 2024 Other Reports | ViewVerify |
Relay Therapeutics Earnings per Share Projection vs Actual
Relay Therapeutics Corporate Management
| Deborah Palestrant | Vice Strategy | Profile | |
| MA MBA | Pres CEO | Profile | |
| Thomas Catinazzo | Chief Officer | Profile | |
| Andy Porter | Chief Officer | Profile | |
| Jim Watters | Chief Research | Profile |
Additional Tools for Relay Stock Analysis
When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.